Goldman Sachs Lifts Tgt on Human Genome Sciences (HGSI) to $30, Sees As Acquisition Candidate
More News related to HGSI
- Human Genome Sciences (HGSI) Submits BLA to U.S. FDA for Hep C Treatment ZALBIN
- Human Genome Sciences Submits Biologics License Application to FDA for ZALBIN(TM)
- Human Genome Sciences and Aegera Therapeutics Announce Initiation of Clinical Trial of Lead IAP Inhibitor HGS1029 in Advanced Lymphoid Tumors
- Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
- Human Genome (HGSI) Receives U.S. FDA Response Letter for Anthrax Treatment Raxibacumab
Goldman Sachs lifted their price target on Human Genome Sciences, Inc. (Nasdaq: HGSI) from $24 to $30, reiterating their Buy rating, citing an optimistic view of Benlysta approval for lupus. The firm suggests the drug has a $4.3 billion blockbuster potential.
The firm said because Benlysta is a scarce asset it makes Human Genome Sciences an "attractive acquisition candidate." The firm set a new implied acquisition value of $34.
Real-Time Market Moving News Two-Weeks FREE http://www.streetinsider.com/premium_content.php
Related Categories
Analyst CommentsRumors
Stocks Mentioned
+0.04Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
